Persistent visual field injury can outlast good acuity after CVT-related intracranial hypertension
A preserved Snellen chart can hide substantial optic nerve injury. In a retrospective cohort from a tertiary intracranial hypertension clinic, adults followed after cerebral venous sinus thrombosis continued to show a meaningful burden of neuro-ophthalmic damage even years after diagnosis, despite the fact that most kept normal central visual acuity.
Nineteen patients entered the analysis, 11 of them women, with a mean age of 33.4 years. Mean follow-up reached 3.4 years after diagnosis of CVT-related intracranial hypertension. The cohort was small, but the signal was clinically uncomfortable: visual acuity remained normal in 84.2% of patients, while 26.3% had severe visual field loss and 15.8% showed retinal nerve fiber layer thinning on optical coherence tomography.
One number deserves immediate attention: headache persisted in 94.7% of patients.
Objective eye testing exposed damage that routine acuity checks can miss
The study used a more demanding visual surveillance strategy than the one often applied in routine follow-up of cerebral venous thrombosis. Best-corrected visual acuity, automated perimetry, and optical coherence tomography with measurement of global peripapillary retinal nerve fiber layer thickness were all incorporated. That combination matters because papilledema and intracranial pressure injury do not always degrade central acuity first. Peripheral field loss, especially when chronic, can advance quietly while the patient still reads reasonably well on a standard chart.
The biology is straightforward. When venous outflow obstruction raises intracranial pressure, the optic nerve head becomes congested, axoplasmic transport falters, and retinal ganglion cell axons are progressively stressed. Once that injury accumulates, a patient may retain useful acuity while losing peripheral visual territory or structural nerve fiber thickness. In practical terms, the eye exam can look reassuring while the optic nerve is still paying the price of sustained pressure.
The cohort’s transverse sinus involvement, present in 78.9% of cases, fits the expected vascular pattern of cerebral venous thrombosis. Complete or near-complete recanalization occurred in 68.4%, yet structural and functional visual abnormalities still persisted in a subset of patients. Recanalization does not automatically reset the downstream consequences of prior intracranial hypertension, especially when papilledema has already produced chronic optic nerve stress.
Headache remained common long after the venous clot had receded
Headache did not fade into the background once the acute thrombosis passed. In this group, 94.7% had persistent headache during follow-up, and the phenotype was most often tension-type headache, seen in 63.2%. Another 26.3% met criteria for medication overuse headache.
This pattern is clinically important because headache after CVT does not map neatly onto a single mechanism. Some patients likely continue to experience pain from residual or recurrent intracranial pressure effects, while others may have evolved into a secondary chronic headache disorder that no longer tracks directly with the original thrombosis. Medication overuse adds another layer, particularly when patients reach for frequent analgesics in the setting of ongoing head pain. Once that cycle is established, symptom control can become harder even if the original venous obstruction has improved.
Persistent headache also complicates follow-up because it can distract attention from the eye findings. A patient with stable or improved subjective headache may still harbor severe field loss. A patient whose headache remains severe may be mislabeled as having only a pain disorder while optic nerve injury quietly progresses. The study’s design makes the point plainly: symptom relief and neuro-ophthalmic recovery are not interchangeable outcomes.
Why normal acuity is not enough in follow-up clinics
The main clinical lesson from this cohort is not that every patient with CVT will progress to blindness. It is that visual acuity alone is too blunt to protect against missed morbidity in CVT-related intracranial hypertension. Central acuity stayed normal in most patients, but a substantial minority had severe perimetric loss, and a smaller subset had measurable retinal nerve fiber layer thinning. Those findings support serial perimetry and OCT in addition to routine bedside vision checks.
This approach mirrors what is already standard in idiopathic intracranial hypertension, where automated perimetry and OCT are commonly used to track papilledema-related injury. The gap in CVT has been the lack of objective, long-term follow-up data. Here, the investigators filled part of that gap with quantitative measures rather than symptom reports alone.
The cohort remains a specialized one. Patients came from a tertiary intracranial hypertension clinic, so the findings cannot be assumed to reflect the broader CVT population. Referral bias likely enriched the sample for persistent symptoms and more complex cases. Even so, the pattern is hard to ignore: if follow-up relies on acuity and headache alone, clinicians may miss the very deficits that matter most for long-term function.
A narrower follow-up strategy could miss the patients who need it most
The pathophysiology of CVT-related intracranial hypertension explains why the eye deserves close surveillance. Venous sinus thrombosis can impede cerebral venous drainage, elevate intracranial pressure, and produce papilledema. Sustained pressure damages the optic nerve at a time when the patient may still feel neurologically intact apart from headache. Once the swelling subsides, the residual injury can remain visible on OCT or perimetry even when the patient appears clinically improved.
For neuro-ophthalmology and neurology practices, the implication is concrete. Follow-up after CVT should not end with a normal acuity screen and a general reassurance that the clot has recanalized. Fields and retinal nerve fiber layer thickness can uncover damage that is otherwise easy to miss. The study also argues for structured headache review, including assessment for medication overuse, because persistent pain may represent an additional chronic burden rather than a simple remnant of the acute event.
This cohort does not answer how often these abnormalities develop across all patients with CVT, nor does it establish which patients are at highest risk for irreversible injury. It does show that a subset of patients can live for years with persistent headache and objective visual deficits after CVT-related intracranial hypertension, even when routine acuity appears preserved.